News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
705,377 Results
Type
Article (41812)
Company Profile (473)
Press Release (663092)
Section
Business (208495)
Career Advice (2013)
Deals (35970)
Drug Delivery (97)
Drug Development (83401)
Employer Resources (169)
FDA (16357)
Job Trends (15055)
News (352299)
Policy (32999)
Tag
Academia (2619)
Alliances (50777)
Alzheimer's disease (1333)
Approvals (16309)
Artificial intelligence (172)
Bankruptcy (363)
Best Places to Work (11803)
Biotechnology (355)
Breast cancer (209)
Cancer (1557)
Cardiovascular disease (129)
Career advice (1678)
CAR-T (110)
Cell therapy (328)
Clinical research (66685)
Collaboration (592)
Compensation (308)
COVID-19 (2609)
C-suite (138)
Data (1490)
Diabetes (189)
Diagnostics (6253)
Earnings (86247)
Employer resources (147)
Events (113835)
Executive appointments (482)
FDA (17139)
Funding (533)
Gene therapy (234)
GLP-1 (654)
Government (4423)
Healthcare (19067)
Infectious disease (2706)
Inflammatory bowel disease (121)
Interviews (309)
IPO (16667)
Job creations (3696)
Job search strategy (1430)
Layoffs (451)
Legal (7945)
Lung cancer (227)
Manufacturing (222)
Medical device (13378)
Medtech (13383)
Mergers & acquisitions (19549)
Metabolic disorders (516)
Neuroscience (1717)
NextGen: Class of 2025 (6747)
Non-profit (4541)
Northern California (1883)
Obesity (295)
Opinion (204)
Patents (133)
People (57991)
Phase I (20936)
Phase II (29431)
Phase III (21756)
Pipeline (622)
Postmarket research (2599)
Preclinical (8946)
Radiopharmaceuticals (255)
Rare diseases (302)
Real estate (6001)
Regulatory (22229)
Research institute (2407)
Resumes & cover letters (351)
Southern California (1637)
Startups (3751)
United States (17008)
Vaccines (594)
Weight loss (210)
Date
Last 7 days (667)
Last 30 days (1956)
Last 365 days (35883)
2025 (1612)
2024 (36337)
2023 (41016)
2022 (52276)
2021 (56763)
2020 (54923)
2019 (47419)
2018 (35697)
2017 (33024)
2016 (32347)
2015 (38398)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (731)
Arizona (211)
Asia (38786)
Australia (6448)
California (4327)
Canada (1555)
China (365)
Colorado (193)
Connecticut (212)
Europe (84560)
Florida (598)
Georgia (146)
Illinois (427)
Indiana (242)
Maryland (697)
Massachusetts (3403)
Michigan (184)
Minnesota (320)
New Jersey (1203)
New York (1215)
North Carolina (839)
Northern California (1883)
Ohio (154)
Pennsylvania (1006)
South America (1107)
Southern California (1637)
Texas (625)
Utah (121)
Washington State (442)
705,377 Results for "protagonist therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Protagonist Therapeutics Reports Granting of Inducement Awards
January 7, 2025
·
2 min read
Press Releases
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
December 19, 2024
·
2 min read
Biotech Bay
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024
Protagonist Therapeutics, Inc. today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and one-on-one meetings at the Jefferies Global Healthcare Conference being held in New York City on June 4-6, 2024.
May 31, 2024
·
2 min read
Biotech Bay
Protagonist Therapeutics to Participate in Upcoming March 2024 Investor Conferences
Protagonist Therapeutics, Inc. announced that they will participate in three upcoming investor conferences.
March 6, 2024
·
2 min read
Press Releases
Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024
November 22, 2024
·
2 min read
Press Releases
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
November 20, 2024
·
2 min read
Biotech Bay
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda
Protagonist Therapeutics, Inc. announces the closing of the worldwide collaboration and license agreement for rusfertide with Takeda, a leading values-based, R&D-driven biopharmaceutical company, disclosed on January 31, 2024.
March 18, 2024
·
1 min read
Biotech Bay
Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) (“Protagonist” or the “Company”) today announced that additional data from the rusfertide Phase 2 REVIVE open label extension study will be the focus of an oral presentation at the European Hematology Association (EHA) Congress being held in Madrid, Spain from June 13-16, 2024.
May 14, 2024
·
2 min read
Biotech Bay
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
Protagonist Therapeutics, Inc. announced it has randomized 241 patients in the ongoing Phase 3 VERIFY clinical trial evaluating rusfertide in polycythemia vera as of and expects to meet the trial’s 250 patient enrollment target by the end of March 2024.
March 26, 2024
·
5 min read
Business
Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update
Protagonist Therapeutics (NASDAQ:PTGX) (“Protagonist” or “the Company”) today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
May 7, 2024
·
11 min read
1 of 70,538
Next
